Literature DB >> 29363026

Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.

Alessandra Iurlo1, Daniele Cattaneo2, Nicola Orofino2, Cristina Bucelli2, Matteo Molica3, Massimo Breccia3.   

Abstract

Entities:  

Year:  2018        PMID： 29363026     DOI： 10.1007/s40261-018-0623-7

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  4 in total

1.  Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.

Authors:  Massimo Breccia; Elisabetta Abruzzese; Alessandra Iurlo; Antonella Gozzini; Alessandro Isidori; Domenica Gangemi; Patrizia Pregno; Giuliana Alimena
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

2.  Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.

Authors:  Alessandra Iurlo; Cristina Bucelli; Daniele Cattaneo; Nicola Orofino; Juri Alessandro Giannotta; Manuela Zappa; Umberto Gianelli; Agostino Cortelezzi
Journal:  Ann Hematol       Date:  2017-08-19       Impact factor: 3.673

Review 3.  Ponatinib in the therapy of chronic myeloid leukemia.

Authors:  Marc Poch Martell; Hassan Sibai; Uday Deotare; Jeffrey H Lipton
Journal:  Expert Rev Hematol       Date:  2016-10       Impact factor: 2.929

4.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245
  4 in total
  6 in total

1.  Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.

Authors:  Takayoshi Tachibana; Satoshi Koyama; Taiki Andou; Yasufumi Ishiyama; Masatsugu Tanaka; Hideaki Nakajima; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2018-12-03       Impact factor: 2.490

Review 2.  Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

Authors:  Deepam Pushpam; Sameer Bakhshi
Journal:  Daru       Date:  2020-01-03       Impact factor: 3.117

Review 3.  Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Authors:  Matteo Molica; Emilia Scalzulli; Gioia Colafigli; Robin Foà; Massimo Breccia
Journal:  Ther Adv Hematol       Date:  2019-03-01

4.  CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.

Authors:  Mathias Schneeweiss-Gleixner; Konstantin Byrgazov; Gabriele Stefanzl; Daniela Berger; Gregor Eisenwort; Chantal Blanche Lucini; Susanne Herndlhofer; Sandra Preuner; Klara Obrova; Petra Pusic; Nadine Witzeneder; Georg Greiner; Gregor Hoermann; Wolfgang R Sperr; Thomas Lion; Michael Deininger; Peter Valent; Karoline V Gleixner
Journal:  EBioMedicine       Date:  2019-11-21       Impact factor: 8.143

Review 5.  Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy.

Authors:  Emanuela Andretta; Caterina Costa; Consiglia Longobardi; Sara Damiano; Antonio Giordano; Francesco Pagnini; Serena Montagnaro; Massimiliano Quintiliani; Chiara Lauritano; Roberto Ciarcia
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

6.  Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.

Authors:  Alessandra Iurlo; Daniele Cattaneo; Silvia Artuso; Dario Consonni; Elisabetta Abruzzese; Gianni Binotto; Monica Bocchia; Massimiliano Bonifacio; Fausto Castagnetti; Sara Galimberti; Antonella Gozzini; Miriam Iezza; Roberto Latagliata; Luigiana Luciano; Alessandro Maggi; Maria Cristina Miggiano; Patrizia Pregno; Giovanna Rege-Cambrin; Sabina Russo; Anna Rita Scortechini; Agostino Tafuri; Mario Tiribelli; Carmen Fava; Gianantonio Rosti; Robin Foa; Massimo Breccia; Giuseppe Saglio
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.